Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 14.70M P/E - EPS this Y 25.00% Ern Qtrly Grth -
Income -52.53M Forward P/E -0.82 EPS next Y - 50D Avg Chg -52.00%
Sales - PEG 0.09 EPS past 5Y - 200D Avg Chg -73.00%
Dividend N/A Price/Book N/A EPS next 5Y -55.00% 52W High Chg -88.00%
Recommedations 2.00 Quick Ratio 4.35 Shares Outstanding 59.97M 52W Low Chg 40.00%
Insider Own - ROA -67.24% Shares Float 27.49M Beta 1.88
Inst Own 8.86% ROE - Shares Shorted/Prior 453.67K/440.51K Price 0.25
Gross Margin - Profit Margin - Avg. Volume 2,105,918 Target Price 3.03
Oper. Margin - Earnings Date Nov 11 Volume 986,607 Change 0.78%
Stealth BioTherapeutics Corp. News
05/12/22 Stealth BioTherapeutics Receives Orphan Drug Designation from FDA for Elamipretide for Treatment of Duchenne Muscular Dystrophy
05/03/22 MITO: Positive Data Despite Miss for MITO
05/02/22 Stealth Bio Posts Disappointing Elamipretide Data From Mid-Stage Geographic Atrophy Study
05/02/22 STEALTH BIOTHERAPEUTICS ANNOUNCES DATA FROM RECLAIM-2 PHASE 2 TRIAL OF ELAMIPRETIDE IN GEOGRAPHIC ATROPHY
04/11/22 Stealth BioTherapeutics Announces $8.5 Million in Equity Financings
04/01/22 MITO: Stealth BioTherapeuticsโ€™ Treatments Gain Momentum
03/31/22 Stealth Bio's SBT-272 Shows Encouraging Action In Huntington's Disease Animal Model
03/30/22 Stealth BioTherapeutics Announces New SBT-272 Data and Trial Initiation
03/28/22 Stealth BioTherapeutics Receives Orphan Drug Designation from FDA for Elamipretide for the Treatment of Friedreich's Ataxia
03/24/22 Stealth BioTherapeutics Announces New Data on Complement Gene Expression and Cell Survival in Dry AMD to be Presented at ARVO (2022)
03:30 PM Stealth BioTherapeutics to Host Virtual Event on the Potential of Elamipretide in Treatment of Geographic Atrophy in Dry Age-Related Macular Degeneration
05:12 AM Stealth BioTherapeutics Showcases New Nonclinical Data From Duchenne Muscular Dystrophy Program
03/16/22 Stealth BioTherapeutics Showcases New Duchenne Muscular Dystrophy Nonclinical Data at the 2022 Muscular Dystrophy Association and Clinical and Scientific Conference
03/14/22 Life Sciences Investor Forum Presentations Now Available for On-Demand Viewing
03/09/22 Stealth BioTherapeutics to Present at Upcoming March Investor Conferences
03/08/22 UPDATE โ€“ Life Sciences Investor Forum: Company Executives Present Live March 10th
02/23/22 MITO: Seeking to Repair Mitochondria to Solve Unsolvable Medical Conditions
02/22/22 Stealth BioTherapeutics to Present at Mitochondria-Targeted Drug Development Summit
02/15/22 Last Patient Completes Treatment in Stealth BioTherapeutics' Phase 2 Geographic Atrophy Clinical Trial

Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate is Elamipretide that is in phase 3 clinical trial to treat barth syndrome, phase 2/3 clinical trial for the treatment of duchenne cardiomyopathy, phase 2a clinical trial to treat friedreich's ataxia, phase 2 clinical trial for the treatment of dry age-related macular degeneration, phase 2 clinical trial to treat leber's hereditary optic neuropathy, and phase 3 clinical trial for the treatment of replisome myopathies. The company's product candidates also include SBT-20 to treat complications of diabetes, renal diseases, ocular diseases, neurodegenerative, Parkinson's, Alzheimer's, Huntington's, and ALS diseases; SBT-550 for rare neurological indications; and SBT-272, a peptidomimetic that targets the mitochondria and stabilizing mitochondrial function under conditions of oxidative stress, as well as SBT 550. Stealth BioTherapeutics Corp was incorporated in 2006 and is based in George Town, the Cayman Islands.

MITO Chatroom

User Image Pushups4Profits Posted - 15 minutes ago

$MITO is she going to do it again ?

User Image mariotto Posted - 1 hour ago

$ALNA $MITO I want state funding and then we get big !!

User Image mariotto Posted - 1 hour ago

$ALNA $MITO wowwwww huuu

User Image mariotto Posted - 1 hour ago

$MITO the good news will come that we are waiting for and then we really go to the moon !! $1 tomorrow

User Image mariotto Posted - 1 hour ago

$ALNA $MITO Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development and commercialization of therapies for diseases involving mitochondrial dysfunction. Its flagship product is Elamipretide, which is in phase 3 clinical trial for the treatment of Barth syndrome, phase 2/3 clinical trial for the treatment of Duchenne cardiomyopathy, phase 2a clinical trial for the treatment of ataxia by friedreich, Phase 2 clinical trial for the treatment of dry age-related macular degeneration

User Image allcharts Posted - 1 hour ago

$MITO NEWS - MITO Gets FDA Designation For Orphan Drug: https://www.youtube.com/watch?v=eCH2ELygpM4

User Image mariotto Posted - 1 hour ago

$ALNA $MITO short shorts will be squeezed

User Image mariotto Posted - 1 hour ago

$MITO it will be great here, $$$$$$$$$$$$$$$$$$$$$$$$$$$

User Image mariotto Posted - 1 hour ago

$MITO $AAPL $MSFT $MITO short shorts will be roasted

User Image mariotto Posted - 1 hour ago

$AAPL $MSFT $MITO FDA granted orphan drug designation for elamipretide to treat Duchenne muscular dystrophy., $ 1 tomorrow $$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$

User Image mariotto Posted - 1 hour ago

$AAPL $MITO FDA granted orphan drug designation for elamipretide to treat Duchenne muscular dystrophy., $ 1 tomorrow $$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$

User Image mariotto Posted - 2 hours ago

$ALNA $MITO FDA granted orphan drug designation for elamipretide to treat Duchenne muscular dystrophy., $ 1 tomorrow

User Image mariotto Posted - 2 hours ago

$MITO run here too, $ 1 tomorrow

User Image mariotto Posted - 2 hours ago

$ALNA $MITO

User Image mariotto Posted - 2 hours ago

$ALNA $MITO to the moon

User Image Natalie777 Posted - 2 hours ago

$ALNA and $MITO congrats BULLS!!!

User Image mariotto Posted - 2 hours ago

$ALNA $MITO green green green

User Image mariotto Posted - 2 hours ago

$ALNA $MITO undervalued, they should be worth dollars and not cents, close to the big upside

User Image mariotto Posted - 2 hours ago

$ALNA $MITO it's time to go to the moon $ 1 tomorrow

User Image mariotto Posted - 2 hours ago

$MITO but the owners are not able to make it go up with so few volumes it would be a moment to make them do + 50%

User Image mariotto Posted - 2 hours ago

$MITO ๐Ÿš€๐Ÿš€๐Ÿš€๐Ÿš€๐Ÿš€๐Ÿš€๐Ÿš€๐Ÿš€๐Ÿš€๐ŸŒ’ $1 tomorrow

User Image MickyD Posted - 3 hours ago

$MITO this won't go above 23 cents... ๐Ÿ˜ž

User Image StocksToRiches Posted - 3 hours ago

$NAOV EARNINGS IS OUT TODAY โœ… ๐Ÿ”ฅ https://finance.yahoo.com/news/nanovibronix-reports-first-quarter-2022-123000505.html $HYMC $MITO $PMCB ๐Ÿค‘ Revenue of $272,000, an increase of 164% compared to the prior year period LETS GO ๐Ÿ”ฅ ๐Ÿค‘ ๐Ÿ˜ฑ

User Image LifeChanges Posted - 3 hours ago

$MITO @nurpulad $6k realized profits for the Life Changes team. An incredible effort and amazing results. Congratulations!

User Image shortablestocks Posted - 3 hours ago

Zero shares available to short currently in $MITO. https://www.shortablestocks.com/?MITO

User Image Esgalle Posted - 5 hours ago

$MITO About to be a party up in here!๐ŸŽ‰๐ŸŽ‰๐Ÿค‘๐Ÿค‘

User Image mariotto Posted - 6 hours ago

$ALNA $MITO a year ago it was $ 2, I want to review it soon at that value when we sell the drug

User Image astonmartin13 Posted - 7 hours ago

$MITO er today?

User Image shortablestocks Posted - 7 hours ago

$MITO is short sale restricted for 2022-05-17. https://www.shortablestocks.com/?MITO

User Image hmstocktwits Posted - 7 hours ago

$MITO ๐Ÿ”ฎ

Analyst Ratings
Maxim Group Buy Jul 1, 21
Nomura Buy Apr 3, 20
HC Wainwright & Co. Buy Apr 2, 20
H.C. Wainwright Neutral Dec 23, 19
Cantor Fitzgerald Overweight Sep 27, 19
H.C. Wainwright Buy Jun 18, 19
Nomura Buy Mar 12, 19
BMO Capital Outperform Mar 12, 19